Now showing items 1-2 of 2
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
(Nature Publishing Group, 2014)
This prospective phase II study evaluated the efficacy of azacitidine (Aza)+erythropoietin (Epo) in transfusion-dependent patients with lower-risk myelodysplastic syndrome (MDS). Patients ineligible for or refractory to ...
Investigation of complement component C4 copy number variation in human longevity
Genetic factors have been estimated to account for about 25% of the variation in an adult’s life span. The complement component C4 with the isotypes C4A and C4B is an effector protein of the immune system, and differences ...